JAKARTA. PT Phapros Tbk (PEHA) has posted a net profit of IDR 27.4 billion in the 2022 financial year, growing 143% year-on-year (yoy) or from the previous year which reached IDR 11.3 billion.

Hadi Kardoko, Main Director of PEHA, said that the company's performance in 2022 was supported by operational efficiency, and aggressive market penetration through PEHA's superior products. This is proven by the achievement of one of the company's superior products, namely Antimo, which has entered its 50th year.

“2022 was a year of expansive growth for us. From the aspect of market expansion, product innovation, production volume and others, it resulted in a positive performance compared to the previous year," said Kardoko, through an official statement received by idnfinancials.com.

From the top-line side, PEHA sales in 2022 grew 11% to IDR 1.17 trillion, from the previous year which reached IDR 1.05 trillion. The company's sales growth is claimed to exceed the average growth of the pharmaceutical industry, which only grows in single digits in 2022.

"By looking at last year's performance which increased sharply, we are optimistic that in 2023 PEHA can grow more significantly from a financial and market opportunity perspective, so as to be able to provide better returns to shareholders or investors, employees or other stakeholders," said Kardoko. (KR/LM)